Solae and Novozymes to Develop Next Generation of Soy Proteins
"The partnership with Solae holds great potential and is a good example of how Novozymes' bioinnovation can be utilized in many areas -- in this case to create new healthy solutions for the food industry."
14/10/08 Solae and Novozymes announce their partnership to develop and market new soy proteins with distinctive functional and nutritional benefits. The collaboration combines each company's unique strengths to deliver innovation to consumers. Solae is experienced in developing, producing and marketing soy protein products, while Novozymes contributes enzyme technology to create next generation ingredients with novel benefits for food manufacturers and consumers.
"The partnership with Solae holds great potential and is a good example of how Novozymes' bioinnovation can be utilized in many areas -- in this case to create new healthy solutions for the food industry," says Peder Holk Nielsen, Executive Vice President and head of Novozymes' Enzyme Business.
Both companies are committed to the development of novel soy proteins with enhanced flavor, solubility and nutritional benefits. These game-changing solutions will expand the opportunities for food manufacturers to use soy protein while still meeting consumers' expectations for both flavor and health benefits.
"Our new soy protein ingredients will work in a broader range of food applications, making it easier for consumers across the globe to choose healthy, great tasting foods," said Torkel Rhenman, CEO of Solae, LLC.
Soy proteins are added to a wide range of food products such as infant formulas, meal replacement drinks, sports bars and beverages. As well as increasing the nutritional value of the food, the United States Food and Drug Administration and the Joint Health Claims Initiative in the United Kingdom, among other regulatory bodies, have established that adding soy proteins to food reduces cholesterol levels, thereby lowering the risk of cardiovascular disease.
